Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Kane Biotech Inc. (V:KNE)

Business Focus: Biotechnology & Medical Research (NEC)

Get the company report for the most recent outlook updated daily

Insider Chart - Past 6 Months

Insider Filings

Latest 10 SEDI filings for KNE within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Mar 26, 2024 16:05 ET
Kane Biotech Announces Fourth Quarter and Full Year 2023 Financial Results
Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announces its fourth quarter and full year 2023 financial results. On December 20, 2023, Kane Biotech announced that it received a non-binding offer for its...
Read full article
Mar 20, 2024 08:30 ET
Kane Biotech Extends Exclusivity Period on its Offer for its Interest in STEM Animal Health
Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), announces today that it has extended the exclusivity period on the offer for its interest in STEM Animal Health that it announced on December 20, 2023, from March 19,...
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
0.55
--
--
Price to Sales - TTM
4.80
2.67
3.46
Price to Book - most recent quarter
--
2.57
2.02
Price to Cash Flow per share - TTM
--
6.21
9.70
Price to Free Cash Flow per share - TTM
--
20.97
12.33
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Mar 15, 20242,634-4,425
Feb 29, 20247,0590
Jan 31, 202469-885
See Short Report

Business Summary

Sector:  Healthcare Industry:  Biotechnology & Medical Research

Kane Biotech Inc. is a Canada-based biotechnology company. The Company is engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. It has a portfolio of biotechnologies and products, which includes StrixNB, DispersinB, Aledex, bluestem, bluestem, silkstem, goldstem, coactiv+, coactiv+, DermaKB and DermaKB Biofilm. Its Wound Care & Surgical division is focused on the product development of DispersinB for applications in chronic wound care. Its bluestem product line includes water additives, chews, spray and dental wipes. Its other products in development stage include Coactiv+, antimicrobial wound rinse for use in acute and chronic wounds; Coactiv+, antimicrobial surgical hydrogel for use in surgical and acute wounds, and DispersinB Gel for prosthetic joint infection. It also provides Scalp Detoxifier, Shampoo and Shampoo Bars. Its primary markets for its technologies are animal health and human health.

See business summary

 

Twitter

Search (past week) for $KNE.CA KNE.V

  • No tweets found